US4973594A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Medicaments
Assignee: Glaxo Group Ltd
•
Filing: 1987-12-16
•
Granted: 1990-11-27
•
Expires: 2007-12-16
Abstract
Abstract The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT 3 receptors for the treatment of depression.
Inventors
- 👤 Michael B. Tyers
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:26
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/46; A61K31/41; A61K31/415; A61K31/44; A61K31/445; A61K31/495; A61K31/50; A61K31/55; A61P; A61P25/00; A61P25/24; A61P25/26
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
123 words
A method of treatment of depression which comprises administering to a human or animal subject suffering from depression an effective amount for the treatment of depression of a compound of formula (1): ##STR12## wherein R 1 and R 2 independently represent hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 )alkylamino, mercapto or C 1-4 alkylthio; R 3 represents hydrogen, C 1-4 alkyl, C 3-5 alkenyl, aryl or aralkyl; R 4 represents hydrogen, C 1-7 alkyl, C 3-5 alkenyl, or aralkyl; n is 2 or 3; the free valence is attached to either fused ring, and the azabicyclic ring is in either the exo or endo configuration; or an acid addition salt or quaternary ammonium salt thereof.
Claim 2
Independent Claim
123 words
A method of treatment of depression which comprises administering to a human or animal subject suffering from depression an effective amount for the treatment of depression of a compound of formula (1): ##STR12## wherein R 1 and R 2 independently represent hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 )alkylamino, mercapto or C 1-4 alkylthio; R 3 represents hydrogen, C 1-4 alkyl, C 3-5 alkenyl, aryl or aralkyl; R 4 represents hydrogen, C 1-7 alkyl, C 3-5 alkenyl, or aralkyl; n is 2 or 3; the free valence is attached to either fused ring, and the azabicyclic ring is in either the exo or endo configuration; or an acid addition salt or quaternary ammonium salt thereof.
Claim 3
Dependent Claim
25 words
A method according to claim 1 wherein the compound of formula (i) is (3 α-tropanyl)-1H-indole-3-carboxylic acid ester or a physiologically acceptable salt or solvate thereof.
Claim 4
Dependent Claim
69 words
A method according to claim 1 in which the compound is a compound of formula (i) wherein R 1 and R 2 indpendently represent hydrogen, halogen or C 1-4 alkyl; R 3 represents hydrogen or C C 1-4 alkyl; R 4 represents hydrogen, C 1-7 alkyl or aralkyl; the carbonyl group is attached to the 3-position of the indole ring, and the azabicyclic ring is in the endo configuration.
Claim 5
Dependent Claim
30 words
A method according to claim 1, wherein said compound of formula (i) is administered in a dose of 0.5 μg to 20 mg from 1 to 4 times per day.
Claim 6
Dependent Claim
30 words
A method according to claim 1 wherein said compound of formula (i) is administered in a dose of 0.05 mg to 10 mg from 1 to 4 times per day.
References Cited (Backward Citations)
GB2125398A
Cited
US4803199A
Cited
US4789673A
Cited
US4797406A
Cited
GB2152049A
Cited
EP0189002A2
Cited
GB2169292A
Cited
US4826838A
Cited
US4721720A
Cited
US4721720B1
Cited
GB2193633A
Cited
US4835173A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-11-26 | 1994-05-28 | 1994-11-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-11-26 | 1998-05-28 | 1998-11-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-11-26 | 2002-05-28 | 2002-11-27 | $7700.00 | Window Closed / Lapsed |